The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review
Garside R, Round A, Dalziel K, Stein K, Royle P
Record ID 32003000416
English
Authors' objectives:
The aim of this study is to systematically review the efficacy and cost-effectiveness of imatinib for the treatment of CML in the chronic, accelerated and blast phases, and compare it to existing drug regimes.
Authors' results and conclusions:
The RCTs compared various interferon-alpha (IFN-alpha), hydroxyurea, busulphan and chemotherapy regimens. In the chronic phase, imatinib shows similar 1-year survival to other treatments, but higher complete haematological response (HR) and cytogenetic response (CR) rates. No information on survival beyond 1 year was available.
In the accelerated phase, survival with imatinib appears to be longer than reports for other drugs, but this relies on comparisons of case series. In the blast phase, imatinib appears to show limited longer survival compared to other reports in the literature and complete CR and HR rates for imatinib are within the range of other studies. However, the characteristics of the patients enrolled in these other studies are not well described. There are few studies published and study populations are small. Absence of control groups limits the reliability of the analysis.
Authors' recommendations:
Based on the limited evidence available, imatinib appears to offer an alternative treatment for CML in the accelerated and blast phases.
As yet there is not enough information about imatinib in the chronic phase to draw firm conclusions. Cost-utility estimates for imatinib are particularly sensitive to assumptions about long-term survival, and may be extremely high.
Authors' methods:
Systematic review
Details
Project Status:
Completed
URL for project:
http://www.hta.ac.uk/1259
Year Published:
2002
URL for published report:
n/a
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Costs and Cost Analysis
- Antineoplastic Agents
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.